Daniel Furst, M.D. Joins Medical Advisory Board of Salugen

Daniel Furst, M.D.

Leading physician researchers across various specialties join with Salugen to further the scientific and rational approach to nutrition through nutritional genomics

San Diego, CA (PRWEB) October 16, 2006 -- Salugen, Inc. (www.salugen.com), a leading personalized healthcare company, announced today the expansion of its Medical Advisory Board.

“We are honored to have such well-respected physicians and researchers join our Medical Advisory Board,” says CEO Brian Meshkin. “With their guidance and involvement in our commitment to further the research of genetic and nutritional influences on health conditions, I am very optimistic about the scientific contributions we can make to the field of nutrigenomics.”

Salugen continues to expand its Medical Advisory Board of leading physician researchers across various specialities. Members of Salugen’s Medical Advisory Board include so far:

• Daniel Furst, M.D., UCLA School of Medicine
• Vibeke Strand, M.D., Stanford University School of Medicine
• Michelle Pietzak, M.D., University of Southern California School of Medicine
• Georges Halpern, M.D., Ph.D., Hong Kong Polytechnic University
• Eric Braverman, M.D., Path Medical Foundation, New York City

“I appreciate Salugen’s willingness to take a well-needed scientific and rational approach to nutrition,” said Daniel Furst, M.D., the Carl M. Pearson Professor of Medicine and Director, Rheumatology Clinical Research Center at the UCLA School of Medicine.

Dr. Furst's research interests are in the clinical pharmacology of drugs used to treat rheumatic and autoimmune diseases, including NSAIDs, disease-modifying anti-rheumatic drugs and biological modifiers. He has worked with Salugen management over the past several years on the pharmacogenetics of an anti-folate therapy, methotrexate. He also has an ongoing interest in scleroderma, its pathogenesis, measurement and treatment. He has published more than 300 articles and 10 books. He has served or is serving on the editorial board of Inpharma, Clinical Drug Invest, Drugs, "The Journal of Clinical Rheumatology" and the "Journal of Rheumatology." Additionally, Dr. Furst is an editorial reviewer for professional publications including "Arthritis & Rheumatism," "New England Journal of Medicine," "Journal of Clinical Investigations," "Pharmacotherapy," and the "Journal of Rheumatology."